

RECEIVED

**Complete if Known**

OCT 05 2001

TECH CENTER 1600/2900

A circular stamp from the Office of Intellectual Property (OIP). The text "OIP E" is at the top, "J42" is at the top right, "OCT 02 2002" is in the center, and "PATENT &amp; TRADEMARK OFFICE" is at the bottom.

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Application Number	09/101,413
Filing Date	January 17, 1997
First Named Inventor	Hans Josef Stauss
Group Art Unit	1644
Examiner Name	Ewoldt, G.R.
Attorney Docket Number	RPMS 102

[illegible]

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
		Office. <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
ASE		WO	91/07509	A1	05-30-1991	Massachusetts Inst. of Tech.		
		WO	95/29995	A1	11-19-1995	The Wistar Inst. of Anatomy and Biology		
		WO	97/26328	A1	07-24-1997	RPMS Technology Ltd.		
		WO	00/06602	A1	02-10-2000	H. Sugiyama		
		WO	00/18795	A2	04-06-2000	Corixa Corp.		
		JP	10 218093		07-31-1999	H. Sugiyama		

Examine Signature	<i>F. J. H.</i>	Date Considered	10/17/02
----------------------	-----------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

RECEIVED

Application Number	09/101,413	OCT 05 2002
Filing Date	January 17, 1997	TECH CENTER 1600/2900
First Named Inventor	Hans Josef Stauss	
Group Art Unit	1644	
Examiner Name	Ewoldt, G.R.	
Attorney Docket Number	RPMS 102	

Sheet 2 of 3

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
ASL		AL-OBEIDI, et al., "Peptide and peptidomimetic libraries," <i>Molecular Biotechnology</i> 9:205-223 (1998).	
		BEELEY, "Peptidomimetics and small-molecule drug design: towards improved bioavailability and <i>in vivo</i> stability," <i>TIBTECH</i> 12:213-216 (1994).	
		BLUYSSSEN, et al., "The interferon-stimulated gene 54 K promoter contains two adjacent functional interferon-stimulated response elements of different strength, which act synergistically for maximal interferon-alpha inducibility," <i>Eur. J. Biochem</i> 220: 395-402 (1994)	
		BOTTGER, et al., "Molecular characterization of the hdm2-p53 interaction," <i>J Mol Biol</i> 269:744-756 (1997).	
		BUCKLER, et al., "Isolation, Characterization, and Expression of the Murine Wilms' Tumor Gene (WT1) During Kidney Development," <i>Molecular and Cellular Biology</i> 11(3): 1707-1712 (1991).	
		CROSSLEY & ORKIN, "Phosphorylation of the Erythroid Transcription Factor GATA-1," <i>J Bio Chem</i> 269:16589-96 (1994).	
		GAIGER, et al., "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," <i>Blood</i> 96(4):1480-89 (2000).	
		GAO, et al., "Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specif for WT1," <i>Blood</i> 95:2198-2203 (2000).	
		JANEWAY, et al., <i>Immunobiology</i> 4 <sup>th</sup> Edition (Austin et al., eds.), pages 121, 551, 569, Figures 4.3, 4.5 and 4.7, Garland Press 1999	
ASE		KIEBER-EMMONS, et al., "Therapeutic peptides and peptidomimetics," <i>Curr Opinion Biotechnol</i> 8:436-441 (1997).	

Examiner's Signature	Ewoldt	Date Considered	10/17/02
----------------------	--------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Complete if Known		<b>RECEIVED</b>  OCT 05 2002  TECH CENTER 1600/2900
		Application Number	09/101,413	
Sheet 3 of 3		Filing Date	January 17, 1997	
		First Named Inventor	Hans Josef Stauss	
		Group Art Unit	1644	
		Examiner Name	Ewoldt, G.R.	
		Attorney Docket Number	RPMS 102	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
5/22		MEZIERE, et al., "In vivo helper cell response to retro-inverso peptidomimetics," <i>Journal of Immunology</i> 159:3230-37 (1997).	
		MURALI & GREENE, "Structure-based design of immunologically active therapeutic peptides," <i>Immunologic Research</i> 17(1&2):163-169 (1998).	
		NAKANISHI, et al., "Peptidomimetics of the immunoglobulin supergene family - a review," <i>Gene</i> 137:51-56 (1993).	
		OHMINAMI, et al., "HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide," <i>Blood</i> 95:286-93 (2000).	
		OKA, et al., "Cancer immunotherapy targeting Wilms' Tumor Gene WT1 product," <i>J Immunol</i> 164:1873-80 (2000).	
		OKA, et al., "Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms tumor (WT1) product," <i>Immunogenetics</i> 51:99-107 (2000).	
		SADOVNIKOVA & STAUSS, "Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy," <i>Proc Natl Acad Sci USA</i> 93:13114-13118 (1996).	
		SEMBA, et al., "cDNA cloning and its pronephros-specific expression of the Wilms' tumor suppressor gene, WT1, from <i>Xenopus laevis</i> ," <i>Gene</i> 175: 167-172 (1996).	
		SHARMA, et al., "Molecular Cloning of Rat Wilms' Tumor Complementary DNA and a Study of Messenger RNA Expression in the Urogenital System and the Brain," <i>Cancer Research</i> 52: 6407-6412 (1992).	

Examiner's Signature	Ewoldt	Date Considered	10/17/97
----------------------	--------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+